Inhibition of HSP90 improves CN expression and subsequent Drp1 activation, ultimately attenuating the adventitial remodeling of AngII-induced hypertension, suggesting that HSP90 inhibition is a novel therapeutic approach for the remodeling of hypertension [76]. The gene discussed is DNM1L; the disease is hypertensive disorder.